LMR Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-13,300
Closed -$3.04M – 1421
2025
Q4
$3.04M Hold
13,300
– – 0.01% 712
2025
Q3
$3.08M Sell
13,300
-4,500
-25% -$916K 0.01% 628
2025
Q2
$3.3M Sell
17,800
-6,000
-25% -$1.12M 0.02% 550
2025
Q1
$4.99M Buy
+23,800
New +$4.63M 0.05% 409
2024
Q2
– Sell
-28,600
Closed -$5.21M – 1087
2024
Q1
$5.21M Hold
28,600
– – 0.05% 313
2023
Q4
$4.43M Buy
+28,600
New +$4.17M 0.05% 336

Other funds holding ABBV

LMR Partners's ABBV Position: Q3 2026 in Review

LMR Partners reduced its AbbVie (ABBV) stake by 13% in Q3 2026, selling an estimated $2.64M and leaving 69,445 shares worth $18.2M. The position accounts for 0.06% of the portfolio, ranked #279.

LMR Partners first reported a position in ABBV in Q3 2014 and has held it in 30 quarters since. The position peaked at $20.1M in Q2 2026. 4,280 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • LMR Partners held 69,445 shares of AbbVie worth $18.2M as of Q3 2026.
  • LMR Partners sold 10,291 AbbVie shares in Q3 2026, an estimated $2.64M.
  • AbbVie made up 0.06% of LMR Partners's portfolio in Q3 2026, its #279 holding.
  • LMR Partners first reported a position in AbbVie in Q3 2014 and has held it in 30 quarters since.
  • LMR Partners's AbbVie position peaked at $20.1M in Q2 2026.
  • 4,280 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on LMR Partners's 13F filing for Q3 2026, filed 16 Nov 2026.